Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE3B | Q13370 | 1/20 | 0.45 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.45 |
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
| ▸ | GAA | P10253 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 1/20 | 0.43 |
| ▸ | HTR2C | P28335 | 2/20 | 0.43 |
| ▸ | ACHE | P22303 | 1/20 | 0.42 |
| ▸ | DRD2 | P14416 | 1/20 | 0.42 |
| ▸ | DRD3 | P35462 | 1/20 | 0.42 |
| ▸ | EGFR | P00533 | 1/20 | 0.42 |
| ▸ | PDGFRA | P16234 | 1/20 | 0.42 |
| ▸ | KDR | P35968 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.41 |
| ▸ | CHRNB4 | P30926 | 1/20 | 0.41 |
| ▸ | CHRNA3 | P32297 | 1/20 | 0.41 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.41 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.41 |
| ▸ | SNCA | P37840 | 1/20 | 0.41 |
| ▸ | HTR2A | P28223 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13799420 | 0.87 | ACHE (0.47) | PDE3BPDE3AHTR2CACHEDRD2 | |
| SCHEMBL4138659 | 0.83 | DRD2 (0.47) | PDE3BPDE3AHTR2CDRD2DRD3 | |
| SCHEMBL11354051 | 0.81 | CHRNB2 (0.45) | LMNAGAAMAPTALDH1A1CHRNB2 | |
| SCHEMBL8258749 | 0.81 | PDE3B (0.44) | PDE3BPDE3AGAAHTR2CACHE | |
| SCHEMBL24347621 | 0.78 | DRD2 (0.40) | PDE3BPDE3AHTR2CACHEDRD2 | |
| SCHEMBL7297572 | 0.77 | PDE3B (0.41) | PDE3BPDE3ADRD2DRD3EGFR | |
| SCHEMBL8399480 | 0.77 | PDE3B (0.44) | PDE3BPDE3AHTR2CACHEDRD2 | |
| SCHEMBL7297564 | 0.77 | PDE3B (0.41) | PDE3BPDE3ADRD2DRD3EGFR | |
| SCHEMBL29052203 | 0.76 | DRD2 (0.51) | HTR2CACHEDRD2DRD3CHRNB2 | |
| SCHEMBL7422905 | 0.76 | HTR2C (0.48) | PDE3BPDE3AHTR2CACHEDRD2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20190127345-A1 | NEGATIVE PHOTOCHROMIC MATERIALS WITH TUNABLE PROPERTIES | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2019-05-02 | — | — | US | claimed |
| WO-2017189700-A1 | NEGATIVE PHOTOCHROMIC MATERIALS WITH TUNABLE PROPERTIES | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2017-11-02 | — | — | WO | claimed |
| CN-110437123-B | Method for synthesizing optically pure 2-substituted indoline compound through dynamic kinetic resolution | 华中师范大学 | 2023-01-03 | — | — | CN | disclosed |
| EP-3106453-B1 | METHOD FOR PRODUCING OPTICALLY ACTIVE COMPOUND, AND NOVEL METAL-DIAMINE COMPLEX | TAKASAGO PERFUMERY CO LTD (JP) | 2020-04-08 | — | — | EP | disclosed |
| US-20190127345-A1 | NEGATIVE PHOTOCHROMIC MATERIALS WITH TUNABLE PROPERTIES | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2019-05-02 | — | — | US | disclosed |
| WO-2017189700-A1 | NEGATIVE PHOTOCHROMIC MATERIALS WITH TUNABLE PROPERTIES | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2017-11-02 | — | — | WO | disclosed |
| US-9745229-B2 | Method for producing optically active compound, and novel metal-diamine complex | TAKASAGO INTERNATIONAL CORPORATION (JP) | 2017-08-29 | — | — | US | disclosed |
| EP-3106453-A1 | METHOD FOR PRODUCING OPTICALLY ACTIVE COMPOUND, AND NOVEL METAL-DIAMINE COMPLEX | Takasago International Corporation (JP) | 2016-12-21 | — | — | EP | disclosed |
| US-20160347678-A1 | METHOD FOR PRODUCING OPTICALLY ACTIVE COMPOUND, AND NOVEL METAL-DIAMINE COMPLEX | TAKASAGO INTERNATIONAL CORPORATION (JP) | 2016-12-01 | — | — | US | disclosed |
| US-8623407-B2 | Gabapentin-containing solid compositions and process for preparing the same | PFIZER INC. (US) | 2014-01-07 | — | — | US | disclosed |
| US-8623407-B2 | Gabapentin-containing solid compositions and process for preparing the same | PFIZER INC. (US) | 2014-01-07 | — | — | US | disclosed |
| US-7309719-B1 | Storage stability; gabapentin and pregabalin, and neutral alpha -amino acid | WARNER LAMBERT COMPANY, LLC (US) | 2007-12-18 | — | — | US | disclosed |
| US-7309719-B1 | Storage stability; gabapentin and pregabalin, and neutral alpha -amino acid | WARNER LAMBERT COMPANY, LLC (US) | 2007-12-18 | — | — | US | disclosed |
| US-20070142351-A1 | Novel heterocyclic amide derivatives and their use as dopamine D3 receptor ligands | AVENTIS PHARMACEUTICALS INC. (US) | 2007-06-21 | — | — | US | disclosed |
| US-20070135426-A1 | LACTAM-CONTAINING COMPOUNDS AND DERIVATIVES THEREOF AS FACTOR XA INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY | 2007-06-14 | — | — | US | disclosed |
| EP-0113921-A2 | Process for the manufacture of stable solutions of cationic methine dyes | BAYER AG (DE) | 1984-07-25 | — | — | EP | disclosed |
| EP-0002721-B1 | PROCESS FOR PREPARING HYDRAZINES | BAYER AG (DE) | 1981-09-02 | — | — | EP | disclosed |
| EP-0002721-A2 | Process for preparing hydrazines | BAYER AG (DE) | 1979-07-11 | — | — | EP | disclosed |
| US-4145537-A | BENZOTHIAZOLIUM DYES | BAYER AKTIENGESELLSCHAFT (DE) | 1979-03-20 | — | — | US | disclosed |
| US-4017484-A | Cationic dyestuffs | BAYER AKTIENGESELLSCHAFT (DT) | 1977-04-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070142351-A1 | Novel heterocyclic amide derivatives and their use as dopamine D3 receptor ligands | DRD3, DRD2, DRD1 | PDE3B 576/4885PDE3A 400/4885LMNA 4092/4885 |
| US-20160347678-A1 | METHOD FOR PRODUCING OPTICALLY ACTIVE COMPOUND, AND NOVEL METAL-DIAMINE COMPLEX | AOC1, ODC1, C5 | PDE3B 588/4885PDE3A 750/4885LMNA 3373/4885 |
| US-20190127345-A1 | NEGATIVE PHOTOCHROMIC MATERIALS WITH TUNABLE PROPERTIES | ALKBH2, YTHDF2, ANXA2 | PDE3B 2944/4885PDE3A 2354/4885LMNA 1426/4885 |
| US-20070135426-A1 | LACTAM-CONTAINING COMPOUNDS AND DERIVATIVES THEREOF AS FACTOR XA INHIBITORS | F12, F2, CPB1 | PDE3B 777/4885PDE3A 1246/4885LMNA 925/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.